Last reviewed · How we verify
NCT05296096: PROXIMUS
PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS
NA trial testing Protein dosage and rehabilitation team delivered exercise prescription in Muscle Loss in 72 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | Boston Children's Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 72 |
| Start date | 20 February 2023 |
| Primary completion | 1 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Protein dosage and rehabilitation team delivered exercise prescription
Conditions studied
- Muscle Loss — all drugs for Muscle Loss →
- Protein — all drugs for Protein →
- Mobility — all drugs for Mobility →
- Pediatric ALL — all drugs for Pediatric ALL →
Sponsor
Boston Children's Hospital
Who can join
Adults 1 to 17, any sex, with Muscle Loss or Protein. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators have designed a 2-center, pilot feasibility, randomized controlled trial (PROXIMUS) to determine the feasibility and safety of a larger multi center, randomized open-label trial comparing high protein combined with individualized exercise vs. standard management during the acute phase of critical illness in children. The investigators aim to determine the impact of the intervention on preservation of muscle mass; and functional status at 1 month and 6 months after randomization.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05296096
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Muscle Loss
Currently open trials in the same condition.
- NCT06728722 — Ultrasound Detection of Body Composition in Critical Care · recruiting
- NCT06458530 — Examining the Effects of Vivo on Physical Function and Glycemic Level in Sedentary Older With Prediabetes. · NA · active not recruiting
- NCT06411964 — Galactooligosaccharide and Aging · NA · recruiting
- NCT06488872 — Comparison of Computed Tomography Data With Routine Measurements Concerning Bone and Muscle Health of Aged Individuals · recruiting
- NCT06136221 — Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease · NA · recruiting
Other Boston Children's Hospital trials
Trials by the same sponsor.
- NCT06804382 — Academic Detailing to Optimize PrEP Implementation in Pediatric Primary Care Settings: ADOPT-PrEP · NA · not yet recruiting
- NCT05113394 — Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy · Phase 2 · withdrawn
- NCT06434220 — Effect of Predictive Model on ED Physician Assessments of Patient Disposition · NA · not yet recruiting
- NCT07476430 — Readiness Outcomes Affecting Return to Sport 3.0 · NA · not yet recruiting
- NCT06706336 — Radon Asthma Intervention Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05296096 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston Children's Hospital
- Last refreshed: 5 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05296096.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing